Early Erythropoietin for Preventing Red Blood Cell Transfusion in Preterm and/or Low Birth Weight Infants

Kc, Praharaj; Halliday, Henry L.; Speer, Christian P.; Gantert, Markus; Jellema, Reint K.; Heineman, Heike; Gantert, Julia; Collins, Jennifer J. P.; Schumacher, Matthias; Lambermont, Verena A.; Keck, Alexander; Garnier, Yves; Zimmermann, Luc J. I.; Kadyrov, Mahmed; Gavilanes, Antonio Wd; Kramer, Boris W.; Soll, Roger F.; Obladen, Michael; Pozo, M.E.; Cave, Andrew; Köroğlu, Özge Altun; Litvin, D.G.; Martin, Richard J.; Fiore, Juliann Di; Giaccone, Annie; Sarikabadayi, Yusuf Unal; Aydemir, Özge; Kanmaz, Gozde; Aydemir, Cumhur; Oğuz, Şerife Suna; Erdeve, Ömer; Eyı, Elif Gül Yapar; Zergeroğlu, Sema; Dilmen, Uğur; Zhou, Qinhua; Wang, Laishuan; Chen, Chao; Cao, Yun; Yan, Weili; Zhou, Wenhao; Parad, Richard B.; Allred, Elizabeth N.; Rosenfeld, Warren; Davis, Jonathan M.; Saugstad, Ola Didrik; Vento, Máximo; Ramji, Siddarth; Howard, Diantha B.; Shah, Prakesh S.; Horst, Hendrik J. ter; Bos, Arend F.; Duijvendijk, Jildou; Hulzebos, Christian V.; Ng, P. C.; Lam, Helena; Patel, Neil; Kirpalani, Haresh; Thukral, Anu; Sankar, Mari Jeeva; Agarwal, Ramesh K.; Gupta, Nidhi; Deorari, Ashok K.; Paul, Vinod K.; Mengensatzproduktion, Satz; Basel, Druck Reinhardt Druck

doi:10.1159/000338550

Cited by 4 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, a meta-analysis of these trials did not show any significant difference in BPD rates [19]. Our study included 478 patients, which is larger than published randomized studies that had <300 patients [11], and showed a significant difference after adjusting for risk factors for BPD.…”

Section: Discussionmentioning

confidence: 73%

“…In previous reports, EPO was shown to decrease the number of RBC transfusions in preterm infants [11,18,19,20,21]. Tempera et al [20] reported an association between EPO treatment and a decrease in ventilator days and speculated on the potential to reduce BPD rates [20].…”

Section: Discussionmentioning

confidence: 99%

“…Previous randomized controlled trials of EPO for AOP have failed to demonstrate any significant difference in rates of BPD [9,10,11]. These studies have reported BPD as a secondary outcome while primarily focusing on transfusion needs.…”

Section: Discussionmentioning

confidence: 99%

“…As a result, to decrease blood transfusions, EPO was administered for treatment of anemia of prematurity (AOP) [9,10,11]. Treatment with EPO, which has the potential to mobilize endothelial progenitor cells (EPC) in animal models [12,13], has been shown to partially reverse the histological features of BPD in rodents [14].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Decrease in Incidence of Bronchopulmonary Dysplasia with Erythropoietin Administration in Preterm Infants: A Retrospective Study

et al. 2012

View full text Add to dashboard Cite

Background: Despite advances in clinical care, the incidence of bronchopulmonary dysplasia (BPD) remains high in premature infants. Erythropoietin (EPO) is used for the treatment of anemia of prematurity (AOP) to decrease blood transfusion needs. EPO has been shown to mobilize circulating endothelial progenitor cells and to enhance lung repair in animal models. Objective: To determine whether EPO treatment for AOP was associated with a reduced incidence of BPD in premature infants. Methods: This retrospective study was performed on all live-born neonates with birth weights from 500 to 1,500 g and gestational age (GA) from 22 to 32 weeks admitted from 1994 to 2002. Infants who received EPO and those who did not receive EPO were compared for incidence of BPD and other morbidities. Results: Of478 patients, 297 received EPO before 36 weeks’ postmenstrual age (group 1) and 181 did not receive EPO (group 2). Group 1 was of similar birth weight but lower GA than group 2. The incidence of BPD was lower in group 1 than group 2 (26 vs. 36%, p = 0.03); after adjusting for significant risk factors, the adjusted odds ratio for BPD was 0.50 (95% CI 0.32, 0.79), p = 0.0028. The BPD rate was much lower when EPO was initiated before 4 weeks of age (16%) as compared to later initiation (44%). Conclusions: This study shows an association between EPO treatment and reduced incidence of BPD in preterm infants, particularly when EPO treatment was initiated within the first 4 weeks of life.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Decrease in Incidence of Bronchopulmonary Dysplasia with Erythropoietin Administration in Preterm Infants: A Retrospective Study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In this issue of Neonatology , Dr. Soll begins with the updated Cochrane review entitled 'Early erythropoietin for preventing red blood cell transfusion in preterm and/ or low birth weight infants' [9] . This is an important update for readers of Neonatology and we hope you enjoy reading it along with Dr. Soll's commentary which puts the findings into context.…”

mentioning

confidence: 99%